Dose-escalated CHOP plus etoposide (MegaCHOEP) followed by repeated stem cell transplantation for primary treatment of aggressive high-risk non-Hodgkin lymphoma

Blood

Volumn 107, Issue 8, 2006, Pages 3058-3064

  Glass, Bertram ^a   Kloess, Marita ^b   Bentz, Martin ^b   Schlimok, Günter ^b   Berdel, Wolfgang E ^b   Feller, Alfred ^b   Trümper, Lorenz ^b   Loeffler, Markus ^b   Pfreundschuh, Michael ^b   Schmitz, Norbert ^b  

^a UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; LACTATE DEHYDROGENASE; PREDNISONE; VINCRISTINE;

ABDOMINAL PAIN; ADULT; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BLADDER DISEASE; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER MORTALITY; CANCER RELAPSE; CANCER RISK; CANCER SURVIVAL; CARDIOTOXICITY; CAUSE OF DEATH; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC TEST; DIARRHEA; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; FEASIBILITY STUDY; FEMALE; GASTROINTESTINAL TOXICITY; HEART ARREST; HIGH RISK PATIENT; HUMAN; INFECTION; LACTATE DEHYDROGENASE BLOOD LEVEL; LIVER TOXICITY; LUNG TOXICITY; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MYELODYSPLASIA; MYELODYSPLASTIC SYNDROME; NEPHROTOXICITY; NEUROTOXICITY; NONHODGKIN LYMPHOMA; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; REFRACTORY ANEMIA WITH EXCESS BLASTS; STOMATITIS; SURVIVAL RATE; SURVIVAL TIME; TREATMENT FAILURE;

EID: 33645738850     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2005-04-1570     Document Type: Article

References (27)

1. Milpied N, Deconinck E, Gaillard F, et al. Initial treatment of aggressive lymphoma with highdose chemotherapy and autologous stem-cell support. N Engl J Med. 2004;350:1287-1295.
2. Haioun C, Lepage E, Gisselbrecht C. et al. Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: final analysis of the prospective LNH87-2 protocol - a groupe d'Etude des lymphomes de l'Adulte study. J Clin Oncol. 2000;18:3025-3030.
3. Gianni AM, Bregni M, Siena S, et al. High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma. N Engl J Med. 1997;336:1290-1297.
4. Santini G, Salvagno L, Leoni P, et al. VACOP-B versus VACOP-B plus autologous bone marrow transplantation for advanced diffuse non-Hodgkin's lymphoma: results of a prospective randomized trial by the non-Hodgkin's Lymphoma Cooperative Study Group. J Clin Oncol. 1998;16:2796-2802.
5. Kluin-Nelemans HC, Zagonel V, Anastasopoulou A, et al. Standard chemotherapy with or without high-dose chemotherapy for aggressive non-Hodgkin's lymphoma: randomized phase III EORTC study. J Natl Cancer Inst. 2001;93:22-30.
6. Kaiser U, Uebelacker I, Abel U, et al. Randomized study to evaluate the use of high-dose therapy as part of primary treatment for "aggressive" lymphoma. J Clin Oncol. 2002;20:4413-4419.
7. Gisselbrecht C, Lepage E, Molina T, et al. Shortened first-line high-dose chemotherapy for patients with poor-prognosis aggressive lymphoma. J Clin Oncol. 2002;20:2472-2479.
8. International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med. 1993;329:987-994.
9. Bearman SI, Appelbaum FR, Buckner CD, et al. Regimen-related toxicity in patients undergoing bone marrow transplantation. J Clin Oncol. 1988;6:1562-1568.
10. Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol. 1999;17:1244.
11. Shipp MA, Neuberg D, Janicek M, Canellos GP, Shulman LN. High-dose CHOP as initial therapy for patients with poor-prognosis aggressive non-Hodgkin's lymphoma: a dose-finding pilot study. J Clin Oncol. 1995;13:2916-2923.
12. del Canizo C, Lopez N, Caballero D, et al. Haematopoietic damage persists 1 year after autologous peripheral blood stem cell transplantation. Bone Marrow Transplant. 1999;23:901-905.
13. Micallef IN, Lillington DM, Apostolidis J, et al. Therapy-related myelodysplasia and secondary acute myelogenous leukemia after high-dose therapy with autologous hematopoietic progenitor-cell support for lymphoid malignancies. J Clin Oncol. 2000;18:947-955.
14. Park S, Brice P, Noguerra ME, et al. Myelodysplasias and leukemias after autologous stem cell transplantation for lymphoid malignancies. Bone Marrow Transplant. 2000;26:321-326.
15. Fisher RI, Gaynor ER, Dahlberg S, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med. 1993;328:1002-1006.
16. Waits TM, Greco FA, Greer JP, et al. Effective therapy for poor-prognosis non-Hodgkin's lymphoma with 8 weeks of high-dose-intensity combination chemotherapy. J Clin Oncol. 1993;11:943-949.
17. Tanosaki R, Okamoto S, Akatsuka N, et al. Dose escalation of biweekly cyclophosphamide, doxorubicin, vincristine, and prednisolone using recombinant human granulocyte colony stimulating factor in non-Hodgkin's lymphoma. Cancer. 1994;74:1939-1944.
18. Juliusson G, Liliemark J. Dose escalation of highdose cyclophosphamide and etoposide with highdose doxorubicin (CDE) and filgrastim for poor-risk non-Hodgkin's lymphoma. Ann Oncol. 1996;7:1037-1041.
19. Meyer RM, Gyger M, Langley R, Lesperance B, Caplan SN. A phase I trial of standard and cyclophosphamide dose-escalated CHOP with granulocyte colony stimulating factor in elderly patients with non-Hodgkin's lymphoma. Leuk Lymphoma. 1998;30:591-600.
20. Meyer RM, Quirt IC, Skillings JR, et al. Escalated as compared with standard doses of doxorubicin in BACOP therapy for patients with non-Hodgkin's lymphoma. N Engl J Med. 1993;329:1770-1776.
21. Haioun C, Lepage E, Gisselbrecht C, et al. Benefit of autologous bone marrow transplantation over sequential chemotherapy in poor-risk aggressive non-Hodgkin's lymphoma: updated results of the prospective study LNH87-2. Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol. 1997;15:1131-1137.
22. Pfreundschuh M, Trumper L, Kloess M, et al. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL. Blood. 2004;104:626-633.
23. Martelli M, Gherlinzoni F, De Renzo A, et al. Early autologous stem-cell transplantation versus conventional chemotherapy as front-line therapy in high-risk, aggressive non-Hodgkin's lymphoma: an Italian multicenter randomized trial. J Clin Oncol. 2003;21:1255-1262.
24. Spielberger R, Stiff P, Bensinger W, et al. Palifermin for oral mucositis after intensive therapy for hematologic cancers. N Engl J Med. 2004;351:2590-2598.
25. Mounier N, Gisselbrecht C, Briere J, et al. Prognostic factors in patients with aggressive non-Hodgkin's lymphoma treated by front-line auto-transplantation after complete remission: a cohort study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol. 2004;22:2826-2834.
26. Stoppa AM, Bouabdallah R, Chabannon C, et al. Intensive sequential chemotherapy with repeated blood stem-cell support for untreated poor-prognosis non-Hodgkin's lymphoma. J Clin Oncol. 1997;15:1722-1729.
27. Schmitz N, Kloess M, Engert A, et al. Repetitive high-dose therapy with dose escalated CHOP plus etoposide followed by autologous stem cell transplantation (Mega-CHOEP) in younger patients with primary diagnosis of aggressive NHL and elevated LDH at diagnosis; final analysis [abstract]. Blood. 2004;104:176a.